Literature DB >> 11470295

Development and optimization of cytokine ELISAs using commercial antibody pairs.

J A Nemzek1, J Siddiqui, D G Remick.   

Abstract

The measurement of cytokines in plasma and other fluids often requires the use of an enzyme-linked immunosorbant assay (ELISA). In the research environment, a valuable assay is one that yields reliable results in the shortest amount of time for the least cost. To achieve this goal, a protocol has been outlined to develop sandwich ELISAs for cytokines using commercial antibodies. These guidelines for ELISA development include selecting antibody concentrations, choosing an appropriate buffer, reducing plasma interference and evaluating the optimal length for incubation periods. In addition, the protocol for a rapid IL-6 ELISA is presented. This ELISA allows measurement of IL-6 in a reduced amount of time by raising the concentration of antibodies used and increasing the temperature for incubation. By following the guidelines presented, cost-effective, cytokine ELISAs can be developed that yield low background, detect a wide range of concentrations, and are suitable for use in the research setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470295     DOI: 10.1016/s0022-1759(01)00419-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  48 in total

1.  Crocetin Potentiates Neurite Growth in Hippocampal Neurons and Facilitates Functional Recovery in Rats with Spinal Cord Injury.

Authors:  Xiqian Wang; Xiejia Jiao; Zhonghao Liu; Yixin Li
Journal:  Neurosci Bull       Date:  2017-08-02       Impact factor: 5.203

2.  Effects of buprenorphine on a cecal ligation and puncture model in C57BL/6 mice.

Authors:  Tara M Cotroneo; Kelly M S Hugunin; Katherine A Shuster; Hae J Hwang; Bala N Kakaraparthi; Jean A Nemzek-Hamlin
Journal:  J Am Assoc Lab Anim Sci       Date:  2012-05       Impact factor: 1.232

3.  Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis.

Authors:  Marcin F Osuchowski; Judith Connett; Kathleen Welch; Jill Granger; Daniel G Remick
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

4.  Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival.

Authors:  Florin L Craciun; Elizabeth R Schuller; Daniel G Remick
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

5.  Antagonism of the Neurokinin-1 Receptor Improves Survival in a Mouse Model of Sepsis by Decreasing Inflammation and Increasing Early Cardiovascular Function.

Authors:  Juan R Mella; Evan Chiswick; David Stepien; Rituparna Moitra; Elizabeth R Duffy; Arthur Stucchi; Daniel Remick
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

6.  The ELISA Standard Save: calculation of sample concentrations in assays with a failed standard curve.

Authors:  Sudha Natarajan; Daniel G Remick
Journal:  J Immunol Methods       Date:  2008-04-28       Impact factor: 2.303

7.  Herbal medicine treatment reduces inflammation in a murine model of cockroach allergen-induced asthma.

Authors:  Jiyoun Kim; Sudha Natarajan; Hyunsu Bae; Sung-Ki Jung; William Cruikshank; Daniel G Remick
Journal:  Ann Allergy Asthma Immunol       Date:  2011-06-12       Impact factor: 6.347

8.  Development of a murine model of blunt hepatic trauma.

Authors:  Jean A Nemzek-Hamlin; Haejin Hwang; Joseph A Hampel; Bi Yu; Krishnan Raghavendran
Journal:  Comp Med       Date:  2013-10       Impact factor: 0.982

9.  Cecal ligation and puncture-induced murine sepsis does not cause lung injury.

Authors:  Kendra N Iskander; Florin L Craciun; David M Stepien; Elizabeth R Duffy; Jiyoun Kim; Rituparna Moitra; Louis J Vaickus; Marcin F Osuchowski; Daniel G Remick
Journal:  Crit Care Med       Date:  2013-01       Impact factor: 7.598

10.  Acute pulmonary lipopolysaccharide tolerance decreases TNF-alpha without reducing neutrophil recruitment.

Authors:  Sudha Natarajan; Jiyoun Kim; Daniel G Remick
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.